FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,795,404 | -41.5% | 277,047 | +30.0% | 0.05% | -57.9% |
| Q3 2022 | $4,777,000 | +128.6% | 213,168 | +295.5% | 0.13% | +37.0% |
| Q1 2022 | $2,090,000 | +2.5% | 53,897 | +56.6% | 0.09% | -36.1% |
| Q3 2021 | $2,040,000 | +61.4% | 34,427 | +136.4% | 0.14% | -5.9% |
| Q2 2021 | $1,264,000 | +104.5% | 14,566 | +94.2% | 0.15% | +70.0% |
| Q1 2021 | $618,000 | – | 7,500 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |